The Study Of Possibility Of Antinuclear Antibody As A Marker For Breast Cancer

Objective: To study the positive rate of antinuclear antibody in the serumof breast cancer patients, intracellular localization and fluorescent features, and to search for the possibility of anti-nuclear antibody as tumor markers.Method: Used indirect immunofluorescence to detect97cases of female breast cancer,52cases of female breast fibroadenoma, and56healthy female serum antinuclear antibodies.Result: antinuclear antibodies were detected in23out of53cancer metastasis patients; a detection rate of43.5%, while there were20of the non-metastasis cancer cases detected with antinuclear antibodies; a detection rate of45.4%, the breast fibroadenoma group detected11anti-nuclear antibody positives; a detection rate of21.2%, the healthy group was detected of9antinuclear antibody positives, a detection rate of16.1%. The positivity rate of antinuclear antibody inmetastatic breast cancer group and non-metastatic breast cancer group is significantly higher (p <0.05) than that of the breast fibroadenoma group and the healthy women group. Furthermore, fluorescent graphics of antinuclear antibodies inthe serum and the positioning within the target antigen cells of metastatic breast cancer group, non-metastatic breast cancer group, breast fibroadenoma groupand healthy women group were all significantly different.Conclusion: The serum antinuclear antibodies in breast cancer patients substantially with the healthy population, further investigation on the basics of the target antigen as well as its biological significance is meaningful for the better understanding of the autoimmune phenomena of breast cancer patients and may be applied to breast cancer diagnosis.